Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25875095 | 0.88 | MEN1 (0.43) | MEN1KMT2AUSP2TSHRCA2 | |
| SCHEMBL16941021 | 0.81 | MEN1 (0.46) | MEN1KMT2AUSP2TSHRTLR2 | |
| SCHEMBL13663154 | 0.74 | MEN1 (0.45) | MEN1KMT2AUSP2TSHRTLR2 | |
| SCHEMBL16941024 | 0.74 | USP2 (0.46) | MEN1KMT2AUSP2TSHRCA2 | |
| SCHEMBL23295081 | 0.73 | KMT2A (0.61) | MEN1KMT2AUSP2TSHRTLR2 | |
| SCHEMBL17175238 | 0.73 | KMT2A (0.61) | MEN1KMT2AUSP2TSHRTLR2 | |
| SCHEMBL22823027 | 0.73 | KMT2A (0.61) | MEN1KMT2AUSP2TSHRTLR2 | |
| SCHEMBL17853874 | 0.73 | KMT2A (0.66) | MEN1KMT2AUSP2TSHRTLR2 | |
| SCHEMBL12706032 | 0.72 | MEN1 (0.49) | MEN1KMT2ATLR2 | |
| SCHEMBL13255060 | 0.72 | MEN1 (0.59) | MEN1KMT2ATLR2KIF11CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212209-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION | 2023-07-06 | — | — | US | disclosed |
| US-20230212209-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212209-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | POLR2H, POLR2E, POLI | MEN1 2649/4885KMT2A 2962/4885USP2 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.